Seeking Alpha

The USPTO has reissued Pfizer's (PFE +1.5%) Celebrex patent, granting it exclusivity to December...

The USPTO has reissued Pfizer's (PFE +1.5%) Celebrex patent, granting it exclusivity to December 2015. The decision gives the drug giant U.S. exclusivity - and a monopoly sales - for an additional 18 months. The reissued patent covers methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex, whose prior patent was previously invalidated by a federal appeals court in 2008.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|